標題：Research Grade Blinatumomab蘭妥莫單抗,AntibodySystem Laboratories

鏈接：https://www.antibodysystem.com/product/6133.html

名稱：Research Grade Blinatumomab 蘭妥莫單抗

別名：Blinatumomab，蘭妥莫單抗，抗體，Bispecific, CD19, AMG103, BITE MT-103, MEDI-538, MT103, bscCD19xCD3

CAS: 853426-35-4

貨號：DHD10804

適用物種：Human

寄主物種：Mus musculus

形式：Liquid

純度：>95%

克隆性：Monoclonal

同種型：(scFv-kappa-heavy)-(scFv-heavy-kappa)

應用：Research Grade Biosimilar

UniProt：P15391 & P07766

靶點：CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain

用途范圍：僅用于科研

儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購買聯(lián)系方式：027-65279366 /18162686757

郵箱：biolab-reagents@atagenix.com

QQ：2663991332

 

參考文獻：

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. PMID: 28249141

Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. PMID: 37099340

Blinatumomab. PMID: 31643524

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. PMID: 36402146

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. PMID: 33651090

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. PMID: 33085860

Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. PMID: 27050240

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. PMID: 33651091

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. PMID: 29358182

Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review). PMID: 34201368

Blinatumomab in Practice. PMID: 38060085

Blinatumomab Conundrum in Low-Risk Relapsed B-Cell ALL. PMID: 37311171

Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. PMID: 30380973

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment. PMID: 37664035

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. PMID: 34767461

Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. PMID: 36279879

Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. PMID: 37257143

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. PMID: 37187201

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. PMID: 34914826

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. PMID: 25524800

Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. PMID: 33153370

Blinatumomab-Associated Neurological Adverse Events. PMID: 32902938

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. PMID: 34979020

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. PMID: 36322825

Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. PMID: 32619115

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. PMID: 32881995

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. PMID: 37131217

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. PMID: 27998223

Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. PMID: 33588145

SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. PMID: 35157496

Blinatumomab: first global approval. PMID: 25637301

Blinatumomab for the treatment of B-cell lymphoma. PMID: 25739952

Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy. PMID: 37417690

Building a better blinatumomab. PMID: 38366135

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma. PMID: 36612039

Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab. PMID: 37822571

Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review. PMID: 37414267

Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. PMID: 33740268